Business
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting OfficerCAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, anno
About this update from Korro Bio, Inc.
[{"type":"image","alt":"Korro Bio, Inc.","displaySize":"","headline":null,"caption":"Korro Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rSREgeXHJL6TSO0VlFoJTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f88b50aee0d9d18bb284f79f2692388e","width":300,"height":56}},"lazy":false},{"type":"text","content":"Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer","length":243,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer.","length":355,"tagName":"p"},{"type":"text","content":"“We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy,” said Ram Aiyar, Ph.D., CEO and President of Korro. “He joins us at an important time as we advance multiple candidates in our pipeline, including KRRO-110, which is currently being evaluated in the Phase 1/2a REWRITE clinical study for Alpha-1 Antitrypsin Deficiency.”","length":486,"tagName":"p"},{"type":"text","content":"“Korro’s unique RNA-editing platform has the potential to bring transformative genetic medicines to patients with rare and highly prevalent diseases and provide hope where there is significant unmet need,” said Dr. Vincent. “I look forward to supporting the mission at Korro and joining its talented management team.”","length":317,"tagName":"p"},{"type":"text","content":"Dr. Vincent joins Korro with more than 20 years in drug discovery and translational research across academia, biotech and the pharmaceutical industry. Throughout his career, Dr. Vincent led teams that advanced more than 20 dr...